Cyclopharm Ltd. | Balance Sheet

Fiscal year is January-December. All values AUD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
1,220.60
3,268.40
6,445.00
4,590.80
8,689.70
6,129.90
Total Accounts Receivable
3,629.00
3,269.00
4,420.50
3,738.20
5,365.60
6,325.40
Inventories
2,581.10
2,284.70
2,208.60
2,633.10
2,677.30
2,771.50
Other Current Assets
20.80
28.00
24.00
98.90
96.30
227.60
Total Current Assets
7,451.50
8,850.00
13,098.10
11,060.90
16,828.80
15,454.50
Net Property, Plant & Equipment
742.40
729.10
631.70
2,340.70
2,682.40
2,468.40
Intangible Assets
3,526.80
706.90
1,311.70
1,717.40
2,767.00
4,570.30
Other Assets
178.40
-
-
-
-
-
Total Assets
11,899.20
10,961.30
16,540.90
16,415.00
23,377.20
23,536.70
ST Debt & Current Portion LT Debt
2,417.00
45.70
45.90
-
87.50
Accounts Payable
1,126.20
901.90
1,049.30
1,796.90
1,561.80
Income Tax Payable
123.00
208.50
475.40
27.80
1,573.10
Other Current Liabilities
1,544.30
1,764.00
1,650.20
1,731.00
1,989.10
Total Current Liabilities
5,210.50
2,920.00
3,220.80
3,555.70
5,211.50
Long-Term Debt
-
200.00
151.50
-
87.30
Provision for Risks & Charges
121.00
72.20
58.50
253.50
212.30
Deferred Taxes
17.20
662.40
1,491.60
1,292.20
1,098.40
Other Liabilities
-
-
-
140.10
616.20
Total Liabilities
5,348.70
3,205.20
3,438.70
3,953.20
6,127.80
Common Equity (Total)
6,550.50
7,756.20
13,102.20
12,461.80
17,249.40
Total Shareholders' Equity
6,550.50
7,756.20
13,102.20
12,461.80
17,249.40
Total Equity
6,550.50
7,756.20
13,102.20
12,461.80
17,249.40
Liabilities & Shareholders' Equity
11,899.20
10,961.30
16,540.90
16,415.00
23,377.20

About Cyclopharm

View Profile
Address
Building 75
Sydney New South Wales (NSW) 2234
Australia
Employees -
Website http://www.cyclopharm.com
Updated 07/08/2019
Cyclopharm Ltd. is a radiopharmaceutical company, which engages in manufacturing and selling medical and health care equipment. It operates through the Technegas and Molecular Imaging segments. The Technegas segment involves in supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism.